105 related articles for article (PubMed ID: 20520543)
21. Outpatient therapy for febrile neutropenia.
Innes H; Marshall E
Curr Opin Oncol; 2007 Jul; 19(4):294-8. PubMed ID: 17545790
[TBL] [Abstract][Full Text] [Related]
22. Risk index for predicting complications and prognosis in Thai patients with neutropenia and fever.
Chayakulkeeree M; Thamlikitkul V
J Med Assoc Thai; 2003 Mar; 86(3):212-23. PubMed ID: 12757060
[TBL] [Abstract][Full Text] [Related]
23. Current approaches for risk stratification of infectious complications in pediatric oncology.
Härtel C; Deuster M; Lehrnbecher T; Schultz C
Pediatr Blood Cancer; 2007 Nov; 49(6):767-73. PubMed ID: 17514729
[TBL] [Abstract][Full Text] [Related]
24. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
Tamura K
Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
[TBL] [Abstract][Full Text] [Related]
25. Ciprofloxacin in treatment of fever and neutropenia in pediatric cancer patients.
Mullen CA
Pediatr Infect Dis J; 2003 Dec; 22(12):1138-42. PubMed ID: 14688588
[TBL] [Abstract][Full Text] [Related]
26. Management of febrile neutropenia in pediatric oncology patients: a Canadian survey.
Boragina M; Patel H; Reiter S; Dougherty G
Pediatr Blood Cancer; 2007 May; 48(5):521-6. PubMed ID: 16724314
[TBL] [Abstract][Full Text] [Related]
27. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century.
Sipsas NV; Bodey GP; Kontoyiannis DP
Cancer; 2005 Mar; 103(6):1103-13. PubMed ID: 15666328
[TBL] [Abstract][Full Text] [Related]
28. Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: A randomized, prospective study.
Ahmed N; El-Mahallawy HA; Ahmed IA; Nassif S; El-Beshlawy A; El-Haddad A
Pediatr Blood Cancer; 2007 Nov; 49(6):786-92. PubMed ID: 17366527
[TBL] [Abstract][Full Text] [Related]
29. Clinical and microbiologic determinants of serious bloodstream infections in Egyptian pediatric cancer patients: a one-year study.
El-Mahallawy H; Sidhom I; El-Din NH; Zamzam M; El-Lamie MM
Int J Infect Dis; 2005 Jan; 9(1):43-51. PubMed ID: 15603994
[TBL] [Abstract][Full Text] [Related]
30. Emergency department waiting times for patients with cancer with febrile neutropenia: a pilot study.
Nirenberg A; Mulhearn L; Lin S; Larson E
Oncol Nurs Forum; 2004 Jul; 31(4):711-5. PubMed ID: 15252427
[TBL] [Abstract][Full Text] [Related]
31. A European Organization for Research and Treatment of Cancer-International Antimicrobial Therapy Group Study of secondary infections in febrile, neutropenic patients with cancer.
Akova M; Paesmans M; Calandra T; Viscoli C;
Clin Infect Dis; 2005 Jan; 40(2):239-45. PubMed ID: 15655741
[TBL] [Abstract][Full Text] [Related]
32. The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies.
Cherif H; Johansson E; Björkholm M; Kalin M
Haematologica; 2006 Feb; 91(2):215-22. PubMed ID: 16461306
[TBL] [Abstract][Full Text] [Related]
33. Risk assessment and treatment of low-risk patients with febrile neutropenia.
Kern WV
Clin Infect Dis; 2006 Feb; 42(4):533-40. PubMed ID: 16421798
[TBL] [Abstract][Full Text] [Related]
34. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer.
Shenep JL; Flynn PM; Baker DK; Hetherington SV; Hudson MM; Hughes WT; Patrick CC; Roberson PK; Sandlund JT; Santana VM; Sixbey JW; Slobod KS
Clin Infect Dis; 2001 Jan; 32(1):36-43. PubMed ID: 11112678
[TBL] [Abstract][Full Text] [Related]
35. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.
Baskaran ND; Gan GG; Adeeba K
Ann Hematol; 2008 Jul; 87(7):563-9. PubMed ID: 18437382
[TBL] [Abstract][Full Text] [Related]
36. Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection.
Ammann RA; Hirt A; Lüthy AR; Aebi C
Med Pediatr Oncol; 2003 Nov; 41(5):436-43. PubMed ID: 14515382
[TBL] [Abstract][Full Text] [Related]
37. [Changes in the epidemiology of infections in patients with febrile neutropenia].
Karthaus M; Carratala J
Wien Med Wochenschr; 2001; 151(3-4):47-52. PubMed ID: 11789419
[TBL] [Abstract][Full Text] [Related]
38. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever.
Santolaya ME; Alvarez AM; Becker A; Cofré J; Enríquez N; O'Ryan M; Payá E; Pilorget J; Salgado C; Tordecilla J; Varas M; Villarroel M; Viviani T; Zubieta M
J Clin Oncol; 2001 Jul; 19(14):3415-21. PubMed ID: 11454890
[TBL] [Abstract][Full Text] [Related]
39. New trends in patient management: risk-based therapy for febrile patients with neutropenia.
Rolston KV
Clin Infect Dis; 1999 Sep; 29(3):515-21. PubMed ID: 10530438
[TBL] [Abstract][Full Text] [Related]
40. Rationalizing the approach to children with fever in neutropenia.
Ammann RA; Tissing WJ; Phillips B
Curr Opin Infect Dis; 2012 Jun; 25(3):258-65. PubMed ID: 22395759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
